Background
POM Wonderful sells pomegranate juice products and competes with Coca-Cola’s Minute Maid division. The Minute Maid product at issue had a label prominently displaying the words “pomegranate blueberry” — despite containing only 0.3% pomegranate juice and 0.2% blueberry juice. The beverage was overwhelmingly apple and grape juice.
POM sued Coca-Cola under §43(a) of the Lanham Act, which prohibits false or misleading descriptions of fact in commercial advertising. Coca-Cola argued the Lanham Act claim was barred because its label had been created in compliance with the Food, Drug, and Cosmetic Act (FDCA), which the FDA administers and which includes detailed juice labeling requirements. The question for the Supreme Court was whether the FDCA’s regulatory scheme precluded a competitor’s Lanham Act false advertising claim.
The Court’s Holding
Justice Kennedy, writing for an 8-0 Court, held that the FDCA does not preclude Lanham Act false advertising claims by competitors. The two statutes serve different purposes and are designed to complement each other. The FDCA protects consumers through government enforcement; the Lanham Act empowers competitors to protect themselves from unfair commercial competition.
The Court rejected the idea that FDA compliance provides a safe harbor from Lanham Act suits. The FDA’s labeling rules were designed to ensure labels are not “misleading” in a general consumer-protection sense, but the agency does not adjudicate competitor claims, does not provide monetary remedies for commercial harm, and cannot substitute for the private enforcement mechanism the Lanham Act provides. Federal statutes are presumed to complement each other unless there is a clear congressional intent to displace one with the other.
Key Takeaways
- FDA approval or regulatory compliance with food labeling rules does not immunize a company from Lanham Act false advertising claims by competitors.
- The FDCA and Lanham Act serve complementary but distinct roles — one provides public enforcement via the FDA, the other private enforcement by injured competitors.
- Companies cannot hide behind regulatory compliance as a complete shield against false advertising claims — truthfulness in the marketplace is independently enforceable.
- This ruling applies in any industry where a federal regulatory scheme governs labeling — pharma, food, beverages, medical devices, and others.
Why It Matters
This decision significantly expanded the practical scope of Lanham Act false advertising claims in regulated industries. Before POM Wonderful, many defendants in food, beverage, and pharma cases argued that FDA compliance was a complete defense. After this ruling, that argument fails.
For companies competing in regulated markets, the decision levels the playing field. Honest manufacturers can hold misleading competitors accountable through Lanham Act litigation even when the FDA has not taken action. For companies that have stretched the limits of compliant-but-deceptive labeling, the risk of private competitor lawsuits is now a real cost to weigh.